TRU-SENTIMENT · DeltaNeutral
GMAB Trading Analysis - 09/30/2026 02:05 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
GMAB (Genmab A/S ADS) at $35.81. True Sentiment Bullish, delta 40-60 call 99% / put 1%, call $4,757,050 vs put $56,345. RSI 74.4.
- Symbol
- GMAB
- Price
- $35.81
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-09-30 14:05:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis — Delta 40–60 Options:Options sentiment: Strongly Bullish
Call dollar volume: $4,757,050.00 (98.80%)
Put dollar volume: $56,345.00 (1.20%)
Total dollar volume: $4,813,395.00
| Measure | Result |
|---|---|
| Call contracts | 18,317 |
| Put contracts | 157 |
| Call trades | 6 |
| Put trades | 3 |
| Filtered true-sentiment trades | 9 |
| Filter ratio | 5.80% |
The call/put dollar ratio is approximately 84.42 to 1, showing unusually strong directional bullish conviction. The data imply that market participants are positioning primarily for appreciation or upside volatility rather than for downside protection.
There is no bearish price-sentiment divergence at present because both indicators lean higher. However, the sentiment sample is narrow: only nine true-sentiment trades remained after filtering, and the filter ratio was just 5.80%. The conclusion is powerful in percentage terms but should be treated as concentrated positioning rather than a broad sample of market activity.
Key Statistics: GMAB
Fundamental Snapshot
Valuation
| P/E (trailing) | 27.50 |
| EPS (trailing 12 mo) | $1.28 |
| Market cap | $22.03B |
| Shares outstanding | 614.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.78 |
| 52-week low | $23.62 |
| 52-week high | $35.66 |
| Historical volatility | 29.7% |
Ownership & trading
| Institutional ownership | 5.3% |
| Average daily volume | 2.0M sh |
Reported figures; no analyst estimates.
📈 Analysis
GMAB Stock Analysis
GMAB combines a strong medium-term price trend with exceptionally bullish options positioning, but the RSI is already overbought and the stock is trading near its 30-day high. The embedded option-spread module therefore recommends waiting for greater alignment between technicals and sentiment.
Overall bias: Bullish | Conviction: Medium
News Headlines & Context:
News context is separate from the data-driven analysis. The embedded dataset does not contain company announcements, filing dates, or earnings dates, so the following are broad themes relevant to Genmab rather than verified events occurring during the supplied September 2026 data window.
- Darzalex franchise remains a central commercial driver. Sales execution for Genzalmyz and other Darzalex indications can materially influence expectations for Genmab’s revenue durability and profitability.
- Pipeline and regulatory updates remain important catalysts. Clinical readouts, regulatory decisions, label expansions, and launch progress across the company’s oncology portfolio can create substantial share-price volatility.
- Development-stage programs provide both upside and risk. Positive data could support the current bullish trend, while trial setbacks, safety issues, or regulatory delays could produce sharp downside reactions.
- Partnership and milestone activity can alter expectations. Collaboration payments, licensing transactions, and commercialization updates may affect the market’s view of the pipeline even when they do not immediately change reported earnings.
These themes are consistent with a biotech trading near new highs: the direction of travel is constructive, but the market may respond sharply to company-specific clinical, regulatory, or commercial developments.
Fundamental Analysis:
| Metric | Value | Assessment |
|---|---|---|
| Current price | $35.81 | Near the supplied 52-week high of $35.66 |
| Market capitalization | $22.03 billion | Substantial biotechnology-company valuation |
| Trailing EPS | $1.28 | Positive trailing earnings |
| Trailing P/E | 27.50x | Growth valuation, but no sector or peer data is supplied |
| PEG ratio | Not provided | Growth-adjusted valuation cannot be assessed |
| Dividend yield | 0.00% | Income is not part of the thesis |
| Beta | 0.78 | Historically lower market sensitivity than a beta of 1.00 |
| Historical volatility | 29.70% | Meaningful volatility and event sensitivity |
| Institutional ownership | 5.31% | Relatively limited institutional participation |
Revenue Growth and Earnings
Revenue growth is not provided, so neither year-over-year growth nor recent acceleration can be calculated. Total revenue is also absent. The available EPS figure of $1.28 confirms positive trailing profitability, but no quarterly EPS history is supplied, making the direction and consistency of recent earnings growth impossible to verify.
Margins and Balance Sheet
Gross margin, operating margin, and net margin are not available. Return on equity, free cash flow, total debt, equity, and debt-to-equity are also missing. Consequently, the dataset does not support conclusions about cash conversion, leverage, or balance-sheet flexibility.
Valuation
At 27.50x trailing earnings, GMAB is not being valued as a low-multiple income or mature value stock. A direct comparison with biotechnology-sector peers cannot be made because no peer multiples are embedded. The requested PEG comparison is also unavailable because the PEG ratio is null. The absence of forward EPS, forward P/E, book value, revenue growth, and consensus data limits a complete valuation assessment.
Analyst Consensus
No analyst recommendation, consensus rating, number of analyst opinions, or mean price target is provided. The market therefore has no embedded analyst target against which to measure the $35.81 current price.
Fundamental Strengths and Concerns
- Strengths: Positive trailing EPS, a $22.03 billion market capitalization, and a 0.78 beta.
- Concerns: No dividend, only 5.31% institutional ownership, and a 27.50x trailing P/E that requires continued execution.
- Data gaps: No revenue growth, margins, ROE, free cash flow, leverage metrics, forward estimates, or analyst targets.
Fundamentally, the available data are compatible with the bullish price trend but incomplete. The technical picture is much stronger than the fundamental evidence because only headline valuation and profitability metrics are available.
Current Market Position:
The latest supplied intraday close is $35.81 as of September 30, 2026 at 13:35. It is above the September 29 daily close of $35.63 and above the 30-day high of $35.70 reported in the indicator file.
| Observation | Level | Significance |
|---|---|---|
| Latest intraday close | $35.81 | Price remains at the top of the recent range |
| 30-day high | $35.70 | Indicators show a break above the prior range ceiling |
| September 29 high | $35.64 | Near-term resistance and breakout reference |
| Bollinger upper band | $36.13 | First volatility and extension barrier |
| 5-day SMA | $35.19 | Nearest trend-based support |
| 20-day SMA | $34.16 | Intermediate support and longer-term trend base |
| 50-day SMA | $32.30 | Major trend support |
Recent and Intraday Price Action
GMAB rose from a September 10 close of $32.23 to $35.63 on September 29, a gain of approximately 10.54%. The September 29 daily volume of 3.51 million shares was about 93.38% above the 20-day average of 1.81 million, confirming strong participation in the advance.
The latest five five-minute bars show a gradual rise from $35.69 to $35.81, interrupted by a temporary dip to $35.66. The largest of these bars reached $35.79 on 104,029 shares, suggesting renewed demand near the prior high. The latest $35.81 close is only $0.11 above that intraday high, so buyers retained control into the final supplied bar.
Technical Analysis:
Technical Indicators
Interactive charts load with JavaScript. This text is the crawlable summary.